PR Newswire Clinical TrialsOriginal article
Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)
Phase 2YA-101Positive
AI Analysis
Summary
Dasher Neuroscience announced completion of patient enrollment in a Phase 2 global clinical trial of YA-101, an AI-derived drug candidate for Multiple System Atrophy. The achievement represents progress in the company's CNS-focused drug development pipeline.
Clinical Trial Data
Phase
Phase 2
Outcome Details
Patient enrollment completed in Phase 2 global clinical trial
Importance:6/10
Sentiment:
0.60
clinical trialPhase 2CNSAI-drivenenrollment completionMSA
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 28, 2026 12:12 PM